Skip to main content
SHANGHAI RENDU BIOTECHNOLOGY CO., LTD. logo

SHANGHAI RENDU BIOTECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 688193 ISIN · CNE1000059K5 LEI · 300300YIUCE4LPCEH293 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 400 across all filing types
Latest filing 2026-04-28 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688193

About SHANGHAI RENDU BIOTECHNOLOGY CO., LTD.

https://www.rdbio.com/en/

Shanghai Rendu Biotechnology Co., Ltd. specializes in the development, manufacturing, and commercialization of molecular diagnostic products. The company leverages its proprietary RNA-based isothermal amplification technology, known as Simultaneous Amplification and Testing (SAT), to provide rapid and sensitive detection solutions. Its product portfolio primarily focuses on clinical diagnostics for infectious diseases, including sexually transmitted infections, respiratory tract infections, and blood-borne pathogens. Rendu Biotechnology offers integrated platforms that combine automated nucleic acid extraction with high-throughput amplification, aiming to improve laboratory efficiency and diagnostic accuracy. By targeting active infection markers through RNA detection, the company provides clinicians with precise tools for disease management and public health monitoring.

Recent filings

Filing Released Lang Actions
立信会计师事务所（特殊普通合伙）关于上海仁度生物科技股份有限公司2025年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report' for the fiscal period ending December 31, 2025. It is issued by a certified public accounting firm (立信会计师事务所) and includes an audit opinion on the effectiveness of the company's internal control over financial reporting. The content focuses on the auditor's responsibilities, the company's responsibilities, and the audit opinion on internal controls. There is no indication that this is a full annual report or interim report, nor is it a brief announcement or certification letter. The document is a standalone audit report specifically about internal control over financial reporting, which fits the definition of an Audit Report / Information (AR). The document length is 2599 characters, which is relatively short but sufficient for an audit report on internal controls. Therefore, the best classification is AR with high confidence. FY 2025
2026-04-28 Chinese
关于公司2025年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the company's 2025 annual profit distribution plan, detailing the proposed cash dividend per share, total dividend amount, and related shareholder meeting approvals. It includes specific dividend ratios, references to the company's board resolutions, and risk warnings related to the distribution. The document does not contain full financial statements or comprehensive financial performance data but focuses on the dividend distribution plan and related disclosures. The document length is 2475 characters, which is relatively short and typical for a dividend announcement rather than a full annual report or interim report. Therefore, this document fits the category of Notice of Dividend Amount (DIV), which covers announcements of dividend amounts, payment dates, and details for shareholders.
2026-04-28 Chinese
关于董事、高级管理人员2026年度薪酬方案的公告
Remuneration Information Classification · 95% confidence The document is an announcement regarding the 2026 annual remuneration scheme for the company's directors and senior management. It details the salary standards, applicable period, and other related provisions. It is not a full report like an annual report or interim report, nor is it a financial statement or earnings release. It specifically focuses on compensation information for executives and directors, which aligns with the definition of Remuneration Information filings. The document is relatively short (1025 characters) and is a formal announcement of the remuneration plan, not a proxy solicitation or voting result. Therefore, the appropriate classification is Remuneration Information (DEF 14A).
2026-04-28 Chinese
上海仁度生物科技股份有限公司2025年度“提质增效重回报”行动方案评估报告暨2026年度“提质增效重回报”行动方案
Management Reports Classification · 90% confidence The document is titled as an "行动方案评估报告" (Action Plan Evaluation Report) for the year 2025 and the plan for 2026, issued by the company's board. It details the company's operational achievements, R&D progress, marketing strategies, governance improvements, investor relations, and shareholder returns. It is a comprehensive narrative on business strategy, performance evaluation, and future plans rather than a formal financial report with detailed financial statements or earnings highlights. The document length is 3797 characters, which is relatively short and reads more like a strategic or management report rather than a full annual or interim financial report. It does not contain quarterly or annual financial statements or earnings highlights, so it is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It also does not fit into categories like Capital/Financing Update, M&A, or Legal Proceedings. The document is more aligned with a Management Report (MDA) because it provides management's detailed explanation of business trends, operational results, and outlook. Therefore, the best classification is Management Reports (MDA).
2026-04-28 Chinese
2025年度独立董事述职报告（徐国良）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2025 from Shanghai Rendu Biotechnology Co., Ltd. It details the independent director's duties, attendance at board and shareholder meetings, oversight of financial reports, internal controls, related party transactions, audit firm appointment, and other governance matters. The content is a narrative report on the independent director's activities and opinions for the year, not a full annual report or financial statement. It is a specialized governance-related report focusing on the independent director's role and performance. This fits best under Board/Management Information (MANG) as it relates to board member duties and disclosures rather than a full Annual Report (10-K) or Audit Report (AR). The document length is under 5,000 characters, but it is a substantive report, not just an announcement. Therefore, the classification is MANG with high confidence.
2026-04-28 Chinese
关于更换保荐代表人的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the change of the company's sponsor representatives (保荐代表人) for ongoing supervision related to the company's IPO and listing on the STAR Market. It details personnel changes and expresses gratitude to the outgoing representatives. There is no financial data, no report attached or referenced as being published, and no mention of voting results or other report types. This fits the category of a management or board-related announcement about changes in key personnel involved in the company's regulatory compliance and supervision. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is short and focused on personnel changes, not a full report or financial disclosure.
2026-04-24 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.